ANNUAL REPORT | 2016-17 Annual Report 2016-17
Total Page：16
File Type：pdf, Size：1020Kb
ANNUAL REPORT | 2016-17 Annual Report 2016-17 BEXIMCO PHARMACEUTICALS LIMITED We take it minute by minute, drop by drop, molecule by molecule. The miracle of a pyramid is in the perfection of every stone. The miracle of life is in the health of every cell. At Beximco Pharma, we are tireless at achieving such perfection in every molecule of our medicines. That's our little contribution to life. Here's to perfection. Here's to life. Mission Contents We are committed to enhancing human health and wellbeing by providing contemporary and affordable medicines, manufactured in full compliance with global About the Company 05 quality standards. We continually strive to improve our core capabilities to address The Board of Directors 06 the unmet medical needs of the patients and to deliver outstanding results for our shareholders. Management Committee 07 Executive Committee 07 Key Events in History 08 Vision Managing Director’s Statement 11 We will be one of the most trusted, admired and successful pharmaceutical companies 2016-17 Highlights 18 in the region with a focus on strengthening research and development capabilities, Post Period Highlights 18 creating partnerships and building presence across the globe. What We Offer 20 Our Global Accreditations 21 Our Manufacturing Capabilities 23 Core Values Research and Development 25 Our core values define who we are; they guide us to take decisions and help realize Our People 29 our individual and corporate aspirations. Beyond Borders 33 Commitment to quality Awards and Accolades 34 We adopt industry best practices in all our operations to ensure highest quality What We Do for the Society 36 standards of our products. Corporate Events 39 Customer satisfaction Notice of Annual General Meeting 45 We are committed to satisfying the needs of our customers, both internal and external. Chairman’s Statement 46 Directors’ Report to the Shareholders 48 People focus Corporate Governance Compliance Report 54 We give high priority on building capabilities of our employees and empower them to realize their full potential. Certificate on Compliance of Corporate Governance Guidelines 57 Report on the Activities of the Audit Committee 58 Accountability Shareholders’ Meeting 60 We encourage transparency in everything we do and strictly adhere to the highest Value Added Statement 62 ethical standards. We are accountable for our own actions and responsible for sustaining corporate reputation. Graphical View of Selected Growth Indicators 63 Corporate social responsibility Independent Auditors’ Report 64 Statement of Financial Position 65 We actively take part in initiatives that benefit our society and contribute to the welfare of our people. We take great care in managing our operations with high concern for Statement of Profit or Loss and Other Comprehensive Income 66 safety and environment. Statement of Changes in Equity 67 Statement of Cash Flows 68 Notes to the Financial Statements 69 Proxy Form and Attendance Slip About the Company Incorporated in 1976, Beximco Pharma started its operation in 1980, importing products from Bayer AG, Germany and Upjohn Inc., USA, which were later manufactured and distributed under licensing arrangement. From that humble beginning, the company has grown from strength to strength, and today it has emerged as a leading manufacturer and exporter of medicines in Bangladesh. Being the only Bangladeshi company listed on AIM of London Stock Exchange, Beximco Pharma has received GMP approvals from all major global regulatory authorities, currently having a global footprint in more than 50 countries across all the continents. With its mission to ensure access to affordable medicines for all, the company is driven by its vision to be among the most admired companies in the region. About the Company | Annual Report 2016-17 | 5 The Board of Management Directors Committee Nazmul Hassan MP Osman Kaiser Chowdhury Managing Director Member of the Board of Directors Rabbur Reza Ali Nawaz Afsar Uddin Ahmed Lutfur Rahman Chief Operating Officer Chief Financial Officer Director, Commercial Director, Manufacturing Shamim Momtaz Mohd. Tahir Siddique Zakaria Seraj Chowdhury Rizvi Ul Kabir Salman F Rahman A S F Rahman Director, Manufacturing Director, Quality Director, International Marketing Director, Marketing Vice Chairman Chairman A R M Zahidur Rahman Jamal Ahmed Choudhury Prabir Ghose M A Arshad Bhuiyan Director, Production Executive Director, Accounts & Finance Executive Director, Quality Assurance Deputy General Manager, Human Resources Nazmul Hassan MP Osman Kaiser Chowdhury Abu Bakar Siddiqur Rahman Iqbal Ahmed Dr. Abdur Rahman Khan Shah Monjurul Hoque Managing Director Director Director Director Independent Director Independent Director Executive Committee Osman Kaiser Chowdhury Member of the Board of Directors Nazmul Hassan MP Managing Director Company Secretary Rabbur Reza Chief Operating Officer Mohammad Asad Ullah, FCS Ali Nawaz Chief Financial Officer Executive Director Afsar Uddin Ahmed Director, Commercial 6 | Annual Report 2016-17 | The Board of Directors Management Committee | Annual Report 2016-17 | 7 1993 Key Events in History 2015-16 2009 1983 2013 2005 2011 1976 1992 2016-17 2008 2006 2014 2003 1980 2010 1985 2012 1976 1980 1983 1985 1992 1993 2003 2005 2006 2008 2009 2010 2011 2012 2013 2014 2015-16 2016-17 - Received GMP approval - Received GMP - Received GMP from the U.S. FDA as the - Russia became the accreditation from approval from ANVISA, - Commenced export first Bangladeshi company first export destination Therapeutic Goods Brazil as the first - Launched generic of ophthalmic - Became the first for formulation Bangladeshi company version of revolutionary Administration (TGA), products to Europe as Bangladeshi pharmaceutical - Launched own products - Received GMP hepatitis C drugs Sovaldi® Australia and Gulf the first Bangladeshi company to commence formulation brands - Started export accreditation from and Harvoni® - Only company in Central Committee for company export of pharmaceutical operations with AGES, Austria (for - Received product Bangladesh to get Drug Registration, for products to the USA. APIs European Union) approval from Health - Company listed on the GCC states as the first Canada as the first - Received approvals for incorporated Alternative Investment Bangladeshi company Bangladeshi company two ANDAs (Sotalol tablets Market (AIM) of - Entered into technology - Launched and Metformin ER tablets) London Stock - Entered the Gulf pharma transfer arrangement to Salbutamol HFA from the US Food and Drug Exchange (LSE) market (Kuwait) as the first manufacture Roche’s inhaler (Azmasol®) Administration (U.S. FDA) through issuance of Bangladeshi company - Entered into the US in Singapore as the - Formed the Company’s - Listed on Dhaka GDRs ARV drug Saquinavir - Won National Export Stock Exchange market through first Bangladeshi Trophy (Gold) for first overseas acquisition of an company the record 5th time manufacturing collaboration - Started manufacturing with the joint venture with Abbreviated New Drug - Received GMP accreditation products of Bayer AG, - Launched CFC free Application (ANDA) as the BioCare Manufacturing (M) - Introduced from Taiwan Food & Drug Sdn Bhd based in Malaysia. Germany and Upjohn HFA inhalers for the only pharmaceutical Inc., USA, under license anti-retroviral (ARV) first time in Administration (TFDA) and - Granted a sub-license by company in Bangladesh agreements drugs as the first Bangladesh Health Canada as the first Medicine Patent Pool of the Bangladeshi company Bangladeshi company UN to produce Bristol-Myers - Exported medicine to Squibb’s new hepatitis C Australia and Romania as the drug Daclatasvir. first Bangladeshi company 8 | Annual Report 2016-17 | Key Events in History Beximco Pharma is entering a new phase of growth and our strategy aims at capitalizing on our competitive advantages Managing Director’s Statement through meaningful alliances, enhancing R&D skills and Dear Shareholders, expansion of capacities. I am pleased to report another successful year for the company with solid performance. Bangladesh continues to achieve sustained economic growth with GDP growing by a record 7.2% in the last year, driven largely by rapid industrialization and robust agricultural output. The country has successfully transformed itself into a state of flourishing economic growth as it seeks to attain middle-income status by 2021. In its ‘Inclusive Growth and Development Report 2017,’ the World Economic Forum commended Bangladesh’s economic progress and ranks the country ahead of India and Pakistan. All of these positive developments give us optimism for the country’s rapid and continued socioeconomic progress in the coming years. Bangladesh Pharma Industry is currently valued at more than $2 billion and the market is growing by double digit for the last few years. Local companies consistently dominate and occupy more than 70% of the total market share. The pharmaceutical industry is one of the most dynamic and technologically advanced industries in Bangladesh. A recent study from London based BMI suggests that Bangladesh’s pharmaceutical industry will continue to expand reaching USD 3.369 billion mark by 2020. Bangladesh’s pharmaceutical sector has the potential to grow at 15 percent for the next five years riding on the expanded domestic market as well as new export frontiers, according to a new research. During the past year, Beximco Pharma registered double digit growth with revenues of BDT 15.5 billion. We have maintained consistent growth